<?xml version="1.0" encoding="UTF-8"?>
<p>A phase I clinical trial for pinocembrin as a new neuroprotective agent reported no adverse effects when 120 mg/day of pinocembrin was administered intravenously to 58 healthy adults for 5 days, which suggests that pinocembrin is safe and well-tolerated [
 <xref rid="B129-molecules-25-02796" ref-type="bibr">129</xref>]. In regards to using pinocembrin as an antiviral drug, more work needs to be done to validate its ability to reduce ZIKV-associated symptoms and neurodegenerative effects as well as to evaluate its safety for use in pregnant women [
 <xref rid="B126-molecules-25-02796" ref-type="bibr">126</xref>].
</p>
